AMENDMENT No. 1 to the Strategic Collaboration, Option and License Agreement between Novartis Pharma AG and Akcea Therapeutics, Inc.Strategic Collaboration, Option and License Agreement • May 9th, 2019 • Akcea Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is entered into as of February 22, 2019 (“Amendment Effective Date”) by and between Novartis Pharma AG, a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”), and Akcea Therapeutics, Inc., a Delaware corporation having its principal place of business at 22 Boston Wharf Road, 9th Floor, Boston, MA 02210, USA (“Akcea”). Novartis and Akcea are each referred to individually as a “Party” and together as the “Parties”.
